Citation Impact
Citing Papers
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
2013
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
2012
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
2009
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
2017 Standout
Guidelines for the welfare and use of animals in cancer research
2010 Standout
Comprehensive molecular portraits of human breast tumours
2012 StandoutNature
Triple negative tumours: a critical review
2007
The promise and challenge of therapeutic genome editing
2020 StandoutNatureNobel
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
2011 Standout
Triple-Negative Breast Cancer
2010 Standout
The DNA-damage response in human biology and disease
2009 StandoutNature
A view on drug resistance in cancer
2019 StandoutNature
Ferroptosis as a p53-mediated activity during tumour suppression
2015 StandoutNature
Accurate classification of BRCA1 variants with saturation genome editing
2018 Nature
Oxidative stress, inflammation, and cancer: How are they linked?
2010 Standout
Influence of Metabolism on Epigenetics and Disease
2013 StandoutNobel
BRCAness revisited
2016
Chromatin Modifications and Their Function
2007 Standout
PARP inhibitor combination therapy
2016
Expanding the Biologist’s Toolkit with CRISPR-Cas9
2015 StandoutNobel
Olaparib: First Global Approval
2015
Playing the End Game: DNA Double-Strand Break Repair Pathway Choice
2012
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Hallmarks of aging: An expanding universe
2023 Standout
Shaping human telomeres: from shelterin and CST complexes to telomeric chromatin organization
2021 Nobel
Modulation of oxidative stress as an anticancer strategy
2013 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Pancreatic cancer
2016 Standout
Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of Aldolase from the Actin Cytoskeleton
2016
In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system
2014 Nature
Towards Understanding the Role of Cancer-Associated Inflammation in Chemoresistance
2009
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
2010 Standout
Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status
2010
Combined immune checkpoint blockade as a therapeutic strategy for BRCA1 -mutated breast cancer
2017
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Mechanisms of resistance to therapies targeting BRCA-mutant cancers
2013
Search-and-replace genome editing without double-strand breaks or donor DNA
2019 StandoutNature
Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy
2014 Nature
The DNA damage response and cancer therapy
2012 Nature
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Targeting DNA repair mechanisms in cancer
2012
Modeling and predicting clinical efficacy for drugs targeting the tumor milieu
2012
Synthetic lethality: the road to novel therapies for breast cancer
2016
Redox-sensitive signaling factors as a novel molecular targets for cancer therapy
2005
Therapeutic potential of PARP inhibitors for metastatic breast cancer
2011
The role of tandem duplicator phenotype in tumour evolution in high‐grade serous ovarian cancer
2011
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
2012 Standout
Synthetic lethality and cancer
2017
The Hallmarks of Aging
2013 Standout
CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes
2016 Standout
The PI3K Pathway in Human Disease
2017 Standout
LRRC8 Proteins Form Volume-Regulated Anion Channels that Sense Ionic Strength
2016 StandoutNobel
Potential cytotoxic and amoebicide activity of first row transition metal compounds with 2,9-bis-(2′,5′-diazahexanyl)-1,1-phenanthroline (L1)
2012
Deconstructing the molecular portraits of breast cancer
2010
Pancreatic cancer
2011 Standout
The mutant p53 mouse as a pre-clinical model
2013
Genome-editing revolution: My whirlwind year with CRISPR
2015 StandoutNatureNobel
Structural and functional photoacoustic molecular tomography aided by emerging contrast agents
2014
Nuclear ADP-Ribosylation Reactions in Mammalian Cells: Where Are We Today and Where Are We Going?
2006
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Structure of the human volume regulated anion channel
2018 StandoutNobel
Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer
2015
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
2016
DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition
2009 Standout
Mesoscopic and Macroscopic Optoacoustic Imaging of Cancer
2015
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
2012
Interactions of anticancer Pt compounds with proteins: an overlooked topic in medicinal inorganic chemistry?
2012
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis
2010
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
Genomic Engineering and the Future of Medicine
2015 StandoutNobel
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Cytokine Storm
2020 Standout
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Topoisomerase levels determine chemotherapy response in vitro and in vivo
2008
DNA origami protection and molecular interfacing through engineered sequence-defined peptoids
2020 StandoutNobel
Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer
2013
The DNA-damage response: new molecular insights and new approaches to cancer therapy
2009
Carbon Nanomaterials for Biological Imaging and Nanomedicinal Therapy
2015 Standout
Cancer Genome Landscapes
2013 StandoutScience
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties
2021 Standout
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
2014 Standout
Advances in Copper Complexes as Anticancer Agents
2013 Standout
Emerging Targets in Photopharmacology
2016 StandoutNobel
Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy
2009
Programmable and Multifunctional DNA‐Based Materials for Biomedical Applications
2018
Accurate proteome-wide missense variant effect prediction with AlphaMissense
2023 StandoutScienceNobel
Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1 -mutated basal-like breast cancer
2007
Etoposide Selectively Ablates Activated T Cells To Control the Immunoregulatory Disorder Hemophagocytic Lymphohistiocytosis
2013
Oxidative Stress and Lipid Peroxidation Products in Cancer Progression and Therapy
2012
Works of Sven Rottenberg being referenced
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
2012
6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2010
The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models
2016
BRCA2-Deficient Sarcomatoid Mammary Tumors Exhibit Multidrug Resistance
2014
Moderate Increase in Mdr1a/1b Expression Causes In vivo Resistance to Doxorubicin in a Mouse Model for Hereditary Breast Cancer
2009
Subunit composition of VRAC channels determines substrate specificity and cellular resistance to P t‐based anti‐cancer drugs
2015
Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin
2013
Modeling therapy resistance in genetically engineered mouse cancer models
2008
BRCA1 RING Function Is Essential for Tumor Suppression but Dispensable for Therapy Resistance
2011
The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells
2018
How do real tumors become resistant to cisplatin?
2008
Cancer cell death by programmed necrosis?
2004
Intra‐operative ex vivo photoacoustic nodal staging in a rat model using a clinical superparamagnetic iron oxide nanoparticle dispersion
2013
Inhibition of apoptosis by intracellular protozoan parasites
2001
What Makes Tumors Multidrug Resistant?
2007
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
2008
Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer
2007
Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer
2015